Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.32 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9991833 | 0.85 | CNR1 (0.32) | ALOX5APFEN1 | |
| SCHEMBL4180779 | 0.81 | CA1 (0.39) | ALOX5APFEN1OPRM1OPRK1PIP4K2A | |
| SCHEMBL9991336 | 0.79 | — | — | |
| SCHEMBL13929775 | 0.79 | CYP2D6 (0.43) | — | |
| SCHEMBL3410101 | 0.79 | ALOX5AP (0.35) | ALOX5APFEN1OPRM1OPRK1PIP4K2A | |
| SCHEMBL31548507 | 0.73 | SPR (0.38) | — | |
| SCHEMBL22941798 | 0.71 | JAK2 (0.34) | ALOX5APFEN1OPRM1OPRK1 | |
| SCHEMBL1025135 | 0.70 | CA1 (0.48) | ALOX5APFEN1 | |
| SCHEMBL31647030 | 0.68 | NAMPT (0.42) | ALOX5APFEN1OPRM1OPRK1PIP4K2A | |
| SCHEMBL15218458 | 0.68 | CYP2D6 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117177975-B | Pyrimido [5,4, D ] pyrimidine compounds, compositions comprising the same and uses thereof | 蒙特利尔大学 | 2026-05-19 | — | — | CN | disclosed |
| US-20250241915-A1 | COMPOUNDS FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | PFIZER INC. (US) | 2025-07-31 | — | — | US | disclosed |
| US-12303509-B2 | Compounds for the treatment of BRAF-associated diseases and disorders | PFIZER INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-20240239801-A1 | PYRIMIDO[5,4,D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2024-07-18 | — | — | US | disclosed |
| EP-4326723-A1 | PYRIMIDO[5,4,D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2024-02-28 | — | — | EP | disclosed |
| CN-117177975-A | Pyrimido [5,4, D ] pyrimidine compounds, compositions comprising the same and uses thereof | 蒙特利尔大学 | 2023-12-05 | — | — | CN | disclosed |
| CN-115515958-B | Novel sulfonamide (Menin-MLL) interaction inhibitor, preparation method and medical application thereof | 成都苑东生物制药股份有限公司 | 2023-09-29 | — | — | CN | disclosed |
| CN-116096710-A | 4-oxo-3, 4-dihydroquinazolinone compounds for the treatment of BRAF related diseases and disorders | 阿雷生物药品公司 | 2023-05-09 | — | — | CN | disclosed |
| EP-4161907-A1 | 4-OXO-3,4-DIHYDROQUINAZOLINON COMPOUNDS FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | Array BioPharma Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| WO-2023011446-A1 | NOVEL SULFONAMIDE MENIN-MLL INTERACTION INHIBITOR, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | 成都苑东生物制药股份有限公司 | 2023-02-09 | — | — | WO | disclosed |
| EP-3950692-A1 | NOVEL TRICYCLIC COMPOUNDS | AbbVie Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| WO-2021250521-A1 | 4-OXO-3,4-DIHYDROQUINAZOLINON COMPOUNDS FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | ARRAY BIOPHARMA INC. (US) | 2021-12-16 | — | — | WO | disclosed |
| US-20210061813-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2021-03-04 | — | — | US | disclosed |
| US-RE47221-E1 | Tricyclic compounds | ABBVIE INC. (US) | 2019-02-05 | — | — | US | disclosed |
| EP-3266786-A1 | NOVEL TRICYCLIC COMPOUNDS | AbbVie Inc. (US) | 2018-01-10 | — | — | EP | disclosed |
| EP-2506716-B1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC (US) | 2017-05-17 | — | — | EP | disclosed |
| US-20160222020-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2016-08-04 | — | — | US | disclosed |
| US-20130216497-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBOTT LABORATORIES | 2013-08-22 | — | — | US | disclosed |
| US-8426411-B2 | Tricyclic compounds | ABBOTT LABORATORIES (US) | 2013-04-23 | — | — | US | disclosed |
| US-20110311474-A1 | Novel Tricyclic Compounds | ABBOTT LABORATORIES (US) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250241915-A1 | COMPOUNDS FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | BRAF, NRAS, RAF1 | ALOX5AP 4278/4885FEN1 3277/4885OPRM1 4709/4885 |
| US-12303509-B2 | Compounds for the treatment of BRAF-associated diseases and disorders | BRAF, NRAS, RAF1 | ALOX5AP 4278/4885FEN1 3277/4885OPRM1 4709/4885 |
| US-20210061813-A1 | NOVEL TRICYCLIC COMPOUNDS | CYP11B2, CYP11B1, ABCB1 | ALOX5AP 1236/4885FEN1 4076/4885OPRM1 290/4885 |
| US-20240239801-A1 | PYRIMIDO[5,4,D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | NRAS, BRAF, KRAS | ALOX5AP 2224/4885FEN1 758/4885OPRM1 3725/4885 |
| US-20160222020-A1 | NOVEL TRICYCLIC COMPOUNDS | CYP11B2, CYP11B1, ABCB1 | ALOX5AP 1236/4885FEN1 4076/4885OPRM1 290/4885 |
| US-20110311474-A1 | Novel Tricyclic Compounds | CYP11B2, CYP11B1, ABCB1 | ALOX5AP 1236/4885FEN1 4076/4885OPRM1 290/4885 |
| US-20130216497-A1 | NOVEL TRICYCLIC COMPOUNDS | CYP11B2, CYP11B1, ABCB1 | ALOX5AP 1236/4885FEN1 4076/4885OPRM1 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.